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That systemic candidiasis increases IN'-cx has been proved in various studies. In our study, we
investigated iffluconazole too, which is used in treatment, has an additional effect on the increase
ofTNF-a. On the sixth dayofthe experimental infection, it was measured that TNF-a levels ofcan-
clidiasis was 699 ± 60pg/ml whereas it was 683 ± 35pg/ml in the mice that wvere treated withflu-
conazole. TNF-a levels were measuredby enzyme-linked immunosorbant assay. Due to thefact that
nostatisticallysignificant difference wasfoundbetween them p > .05) it was thought thatflucona-
zole did not have an additionaleffect on the increase ofTNF-ax in candidiasis.
INTRODUCTION
Tumor necrosis factor-ax (TNF_ct)b
increases as an essential cytokine during
sepsis that is causedby Candida infections.
Candida species activate both the humoral
and the cellular immune systems. Being
the main protector of Candida infections,
cellular immunityconsists ofmacrophages,
neutrophils, mononuclearphagocyte system
and natural killer cells, all orchestrated by
T cells [1]. After activated macrophages
are stimulated by lipopolysaccharide, they
become the largest source ofTNF-az. Other
thanactivatedmacrophages, mastcells, poly-
morphonuclear leukocytes, keratinocytes,
astrocytes, microglia cells, smooth muscle
cells, and tumor cells also release TNF-oc
[2]. It has been demonstrated that similar
to the increase of TNF-a levels during
Candida infections, some antifungal agents
also increase TNF-ax level as a side effect.
Especially during the treatment ofampho-
tericin B (Amp B), systemic side effects are
frequently observed. The increase ofTNF-
x level, which can be both protective and
hanrnfultothe organism, canbe seenamong
the side effects. Fluconazole is the most
frequentlyusedazole-derivated agent, and it
is an antifungal with minimum side-effects
[3]. Whetherfluconazole activates TNF-a or
nothas been investigated inasmallnumber
ofin vitro [4, 5] and in vivo studies [6, 7].
Thepurpose ofourstudy is to measure
TNF-cx level on the experimental model of
murine candidiasis andto investigate ifflu-
conazole hasaneffectonTNF-alevelornot.
aTo whomallcorrespondence should beaddressed:Ayse Kalkanci M.D., Ph.D., Emek Mah.
75. Sok 120/4 06510,Ankara, Turkey; Tel.: 90-312-214-10-00/6914; Fax: 90-312-213-98-02;
E-mail: aysekalkanci@email.com.
bAbbreviations:Amp B, amphotericin B; OD, optic density; PBS, phosphate buffered saline;
TNF-a, tumor necrosis factor-a
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MATERIALS AND METHODS
Experimental animals
Female, six-to eight-week-old, 20to25
g BALB/c mice, maintained from
Hifzisihha Serum Farm, Ankara, Turkey
where the mice were bred under,standard
conditions.
Organisms
C. albicans ATCC 26555 (Kukens,
Istanbul, Turkey) reference strainwereused.
Thepreparation ofyeastsuspensions
Four or five colonies ofCandida albi-
cans, which hadbeen formed in sabouraud
dextrose agar (SDA, Oxoid) after 48-hr
incubation, weresuspended inS mlofsterile,
pyrogen-free, 0.9 percent NaCl. Organisms
were harvested by low-speedcentrifugation
(1500 xg), washed three times in sterile
saline, counted with a hemocytometer and
suspended to 3 x 108 cell/ml concentra-
tion. Mice were challenged by tail vein
injection with 0.2 ml ofsuspension 99 per-
cent of which was blastoconidia [8, 9].
Experimental groups are shown in Table 1.
Measurement ofSerum TNF-a
Blood was collected from the heart.
SerumTNF-alevelswerequantifiedbyusing
enzyme-linked immunosorbant assay kit
called Biosource CytoscreenT Mouse
TNF-cx New Format (United States) [10].
Demonstration ofCandida infection
Both ofthe kidneys were isolated and
incubated to show Candida infection. Both
ofthe kidneys homogenized in 10 mlphos-
phate-buffered saline were inoculated in
equal amounts into SDAplates which con-
tain 100 IU penicillin and 10 ,ug strepto-
mycine. The same homogenized suspen-
sions were also inoculated into blood agar
plates in order to eliminate the presence of
bacterial infections. All ofthe yeast colonies
were counted and documented after a 48-
hr incubation period [8].
Statistical analysis
All statistical analysis were calculated
bythe help ofthe computerprogram, SPSS
9:01. Thegraph(Figure 1) whichshowsthe
optic density (ODs) values that correspond
tothe standards ofTNF-a, was drawn with
regression analysis method (y = -35.189 +
468.621 XOD and R2 = 0.993)
Table 1. Experimental groups.
Main Groups Subgroups Injections Number of Mice
Control Healthy - 16
Saline 0.2 mL 0.9% NaCI* 6
Fluconazole 2 mg/kg fluconazole* 6
Fluconazole 4 mg/kg fluconazole* 6
Fluconazole 10 mg/kg fluconazole* 6
Infection C. albicans 3 x108 yeast/ml** 6
Treatment C. albicans + fluconazole 3 x 108 yeast/ml + 6
10 mg/kg fluconazole***
Total 7 52
*Injections were applied every 24 hrfortwodays.TNF-a levels were measured on the 48th hr.
**TNF-a levels were measured six days after the only yeast suspension was injected.
***On the fourth day of the infection the treatment offluconazole was started, was applied
every 24 hr for two days. On the sixth day of the infection TNF-a levels were measured.Kalkanci and Kustimur: The effect offluconazole on TNF-a production 243
Table 2. TNF-uc levels of the experimental groups.
ODs TNFixt levels Mean values of
(pg/mI) TNF-cx(pg/mi)
2mg/kg 154 36
100 11 20±14
100 11
Control 4mg/kg 108 15
Groups 110 16 15±1.1
105 14
10Omg/kg 128 24
148 34 29±4.7
135 28
Treatment C. albicans 1453 645
Group +Fluconazole 1602 715 683 ±35
(10Omg/kg) 1544 688
Figure 1. TNF-a levels of all groups.
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All of the TNF-a values were calcu-
lated with the help of this equation.
Friedmantest, Mann-Whitney Utest,Kruskal-
Wallis VarianceAnalysis wereusedwiththe
help of the computer programme, SPSS
9:01. Thatthep valuewas smallerthan.01 or
.05 in the statistical evaluations was con-
sidered as a significant difference.
RESULTS
The average of TNF-cz levels of all
groups isshown intheFigure 1. Theaverage
ofTNF-a level wasmeasuredtobe 20pg/ml
inthe group given 2 mg/kg fluconazole, 15
pg/mlinthegroupgiven4mg/kgfluconazole,
and 29 pg/ml in the group given 10 mg/kg
fluconazole. A statistically significant dif-
ferencewas notfoundamongthethreegroups
thatweregivendifferentdoses offluconazole
(p > .05).
The average of TNF-x level was <3
pg/ml inthe healthycontrol group andalso
inthe saline control group which was used
as a solvent offluconazole. There was not
a statistically significant difference among
the healthy control, saline control, and flu-
conazole control groups (p > .05).
Candida colonies were identifed from
the cultures of the kidneys. Mean of the
colonies was 28 ± 1.5 ofthe cultures. The
average of TNF-ac level was measured to
be 683 pg/ml inthe treatment group. It was
699pg/mil inthe C. albicans infectedgroup
that was leftwithouttreatment. Therewasno
statistically significant difference between
the two groups (p > .05).
DISCUSSION
Today the treatment ofCandida infec-
tion is limitedto theuseofantifungalagents.
After infection occurs antifungal agents can
be used to directly destroy the causative
agent ofthe infection or it can be used as a
non-specific profilactic agent against colo-
nization before the infection. AlthoughAmp
B is considered to be the most favorable
antifungal to oppose the life-threatening
infections, recently non-toxic azole anti-
fungal agents have begun to be prefered to
Amp B due to the latter's side effects.
Fluconazole is a preperation that can be
used systemically and orally. The efficiency
offluconazole has decreased because ofits
wide use since the beginning of 1990s.
Despite the resistance problem, flucona-
zole still continues to be used all over the
world [3].
In ourstudy we investigated ifvarying
doses of systemically administrated flu-
conazole increased TNF-a or not. As was
said in the result section, there was not a
statistically significant difference amongthe
three groups to which different doses of
fluconazole were applied. That there was
not a statistically significant difference
between the healthy control group and the
three fluconazole control groups made us
believe that fluconazole by itself did not
have an augmentative effect on TNF-x
level.Accordingto ourresults, itwasthought
that during the infection, fluconazole did
not have an additional effect on TNF-a
levels, independent ofthe effect ofC. albi-
cans. In an in vitro study on the subject it
was found that there was not a statistically
significant differencebetween TNF-ax levels
of the peritoneal macrophages cultures of
mice incubated with C. albicans plus flu-
conazole and the TNF-a levels ofthe cul-
tures incubated solely with C. albicans [4].
InthestudyofYamaguchi etal.,theimmuno-
modulating activity of antifungal drugs
was reviewed. Fluconazole, which has no
immunologic effect, did not induce in vitro
TNF-oc production by macrophages,
whereas Amp B slightly but substantially
does so [5]. Pitzurra et al. have shown that
treatmentwith fluconazole inducedaneffect
on macrophages similar to that ofprome-
ters ofTNF-oc synthesis and secretion [6].
Inthe study ofBaltch et al., it was evaluated
thatthe effects ofcytokines, used singlyand
in combination, onthe microbicidal activity
ofhuman monocyte-derived macrophages
against intracellular C albicans in thepres-
ence and absence of fluconazole. TheirKalkanci and Kustimur: The effect offluconazole on TNF-o production 245
results demonstrate that in the presence of
low concentrations offluconazole, selected
cytokines and their combinations signifi-
cantly increase the microbicidal activity of
human-monocyte derived macrophages
against intracelluar C. albicans [7]. In an
another study it was demonstratedthat flu-
conazole did not increase TNF-ax level in
cerebrospinal fluid of the patients with
coccidioidal meningitis [11].
As a result, fluconazole, which was
demonstrated to be ineffective on TNF-a
level, was emphasized once more as a safe
antifungal agent.
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